NewLimit raises $130M to advance age-reversing treatments

NewLimit, a biotech startup co-founded by Coinbase CEO Brian Armstrong, has raised $130 million in a Series B funding round led by Kleiner Perkins. According to TechCrunch, the company is developing treatments to genetically reprogram aged cells to restore youthful functions, with early lab results showing promising effects on liver cells. Investors include Nat Friedman, Daniel Gross, Khosla Ventures and Founders Fund. While human trials are still a few years away, NewLimit plans to accelerate drug discovery using AI-driven simulations.